The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known ...

The stock shot up 12.5% ahead of the open ... Product sales were also up 22%. Sales of Repatha, Amgen’s cholesterol drug, increased 33% year over year to $517 million, the company said.